11
Recommendations for
Symptom Frequency
Recommendations for
Symptom Severity
Patient
Preference
Intermittent Persistent Mild Severe
++ ++ ++ ++ High
++ + + No High
++ +
b
++ + High
No Yes Yes Not as
monotherapy
Low
Table 10. Comparison of Features of SCIT and SLIT (cont'd)
SCIT SLIT
FDA status FDA approved • SLIT aqueous FDA "off-label" use
• SLIT tablets approved by FDA in April
2014; limited number of allergens
available for treatment
Socioeconomic • CPT code exists
for SCIT vial
preparation and
injections
• Covered by most
insurance plans
• No CPT code exists for SLIT aqueous
preparation
• SLIT aqueous not covered by most
insurance plans
• SLIT tablet insurance coverage to be
determined by individual insurance
carriers